Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: Enhanced cell survival and therapeutic benefits of IL-10-expressing multipotent mesenchymal stromal cells for muscular dystrophy

Fig. 3

Safe systemic treatment with IL-10-expressing hDPSCs in the CXMDJ model. a Transplantation schedule. b Quantitative measurement of IL-10 expression in 2-day culture medium and in the hDPSC lysate (100 mg protein) using ELISA. Data are presented as mean ± SD, and statistical differences between hDPSCs vs. IL-10-hDPSCs are indicated (****P < 0.001, n = 3). c Cytokine and chemokine expression in 2-day culture media of hDPSCs and IL-10-hDPSCs analyzed using the Proteome ProfilerTM Array. Changes in the expression levels of monocyte chemotactic protein-1 (MCP-1), and stromal-derived factor-1 (SDF-1/CXCL12), compared to the positive control (PC) signals or negative control (NC). Signal intensity in the regions of interest (ROIs) quantified using array images (upper panels) and representative data (graph) are presented. ND, not detected. d Growth curve of untreated CXMDJ (control DMD; 14102MA), hDPSC-, and IL-10-hDPSC-treated CXMDJ (hDPSC-DMD, 14105MA; IL-10-hDPSC-DMD, 14108MA) dogs. Data are presented as mean ± SD, and statistical differences between control DMD vs. IL-10-hDPSC-DMD (****P < 0.001), hDPSC-DMD vs. IL-10-hDPSC-DMD (####P < 0.001) are indicated; one-way ANOVA. e Serum levels of IL-10 at 6, 24, and 48 h, and 7 days after transplantation (n = 3), quantified using ELISA. Data are presented as mean ± SD, and statistical differences between control DMD vs. IL-10-hDPSC-DMD (****P < 0.0001), hDPSC-DMD vs. IL-10-hDPSC-DMD (###P < 0.001, ####P < 0.0001) are indicated; ns, not significant, two-way ANOVA

Back to article page